Thymoquinone Effect on Leishmania tropica/infantum and Leishmania-Infected Macrophages

Amir KarimiPourSaryazdi1, Mohammad Mahdi Jafari2, Majid Pirestani3

  • 1Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Acta Parasitologica
|August 17, 2023
PubMed
Abstract

Insights

Thymoquinone, derived from Nigella Sativa, effectively kills Leishmania parasites within macrophages. This natural compound shows promise as a novel therapeutic agent against Leishmania infections.

Area of Science:

  • Parasitology
  • Pharmacology
  • Immunology

Background:

  • Leishmania parasites infect macrophages, evading immune defenses and causing tissue damage.
  • Current Leishmania treatments face challenges like adverse effects and parasite resistance.
  • Thymoquinone, a compound from Nigella Sativa, exhibits antimicrobial and antiparasitic properties.

Purpose of the Study:

  • To investigate the efficacy of Thymoquinone against Leishmania tropica and Leishmania infantum.
  • To evaluate Thymoquinone's impact on Leishmania-infected macrophages in vitro.

Main Methods:

  • In vitro assessment of Thymoquinone's effect on Leishmania promastigotes and amastigotes.
  • Flow cytometry and MTT assays to determine cytotoxicity and apoptosis induction.
  • Amastigote assays to quantify macrophage infection and parasite load.

Main Results:

  • Thymoquinone significantly reduced Leishmania-infected macrophage percentages (e.g., 23% for L. tropica at 20 μM).
  • Thymoquinone induced apoptosis in Leishmania parasites (33.9% in L. tropica, 31.4% in L. infantum).
  • Inhibitory concentrations (IC50) for Thymoquinone were 9.49 μM (L. tropica) and 12.66 μM (L. infantum).

Conclusions:

  • Thymoquinone demonstrates significant lethal activity against both Leishmania promastigote and amastigote forms.
  • The study suggests Thymoquinone's potential as a therapeutic agent for Leishmania infections.